葵花药业集团股份有限公司（以下简称"公司"或"本公司"）董事会于近 日收到公司副总经理、内部审计负责人李金明先生，副总经理朱晓南女士的辞职 报告，李金明先生因个人退休原因申请辞去公司副总经理、内部审计负责人职务， 朱晓南女士因个人原因申请辞去公司副总经理职务。上述人员辞职后不再担任公 司（含子公司）任何职务。 根据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等相关法律、法规及《公司章程》的规定， 李金明先生、朱晓南女士的书面辞职报告自送达公司董事会之日起生效。 证券代码：002737 证券简称：葵花药业 公告编号：2024-047 葵花药业集团股份有限公司 关于高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、高级管理人员辞职情况 二、其他事项说明 2024 年 9 月 30 日 2 李金明先生、朱晓南女士出具的书面辞职报告。 1 特此公告。 葵花药业集团股份有限公司 董 事 会 截至本公告日，李金明先生不直接持有公司股份，其在公司 2022 年员工持 股计划中持有的投资份额，按 ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-048 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第四届董事会第二十九 次会议、第四届监事会第二十二次会议、公司 2023 年年度股东大会审议通过， 公司决定使用额度不超过 200,000 万元的闲置自有资金进行现金管理，存续期为 自股东大会审议通过之日起 12 个月内，在已审议的额度、期限内，资金可循环 滚动使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《中国证券报》、《证券时报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 38,000 万元购买了部分理财 产品，具体情况如下： | 序 | | | | 金额 | | | 预期最 | 资金 | | --- | --- | --- | - ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-046 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 | 序 | | | | 金额 | | | 预期最 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 签约机构 | 产品名称 | 产品类型 | | 起息日 | 到期日 | 高年化 | | | 号 | | | | （万元） | | | 收益率 | 来源 | | | 中国银行 | 挂钩型结构性 存款（机构客 | 保本保最 低收益型 | | | | | 闲置 | | 1 | 哈尔滨香 | 户） | | 30,000.00 | 2024.9.18 | 2024.10.23 | 1.95% | 自有 | | | 坊支行 | 【CSDPY20240 | | | | | | 资金 | | | | 565】 | | | | | | | 1 | | | 注：公司与上述签约机构不存在关联关系。 二、风险及控制措施 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 ...

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company, Kew Flower Pharmaceutical (葵花药业), has a strong financial performance with a Return on Equity (ROE) of 22.4% in 2023, surpassing major competitors in the traditional Chinese medicine sector [1][2] - Kew Flower Pharmaceutical has established a significant market presence with two major products generating over 6 billion and 10 billion in sales, respectively, alongside nearly a hundred products exceeding 10 million in sales [13][15] - The company has invested heavily in marketing, spending 74 billion over six years, which has contributed to its brand recognition and market penetration, particularly in the OTC market [20][21] Summary by Sections Financial Performance - In 2023, Kew Flower Pharmaceutical achieved revenues of 57 billion and a net profit of 11 billion, with a compound annual growth rate (CAGR) of 8.57% in revenue and 15.7% in profit over the past decade [15][16] - The company’s marketing expenses have decreased as a percentage of revenue, indicating improved efficiency in brand establishment [21] Product Portfolio - The company’s product lineup includes two major products: the pediatric lung heat cough syrup series and the liver protection tablets, both of which are market leaders in their respective categories [4][9] - Kew Flower Pharmaceutical has a diverse product range with 1,126 approved drug varieties, including 555 in the national medical insurance directory and 283 essential drug varieties [13] Market Strategy - The company focuses on the OTC market, with 80% of its revenue coming from this segment, leveraging advertising to build brand image and consumer loyalty [17][19] - Kew Flower Pharmaceutical has a strong advertising presence, having launched 2,194 advertisements, which has significantly enhanced its brand visibility [17] Research and Development - The company has invested only 7 billion in R&D over six years, which is less than 10% of its marketing expenditure, raising concerns about its long-term innovation capabilities [22][23] - Kew Flower Pharmaceutical has shifted towards acquiring existing products rather than developing new ones, which may limit its future growth potential [24][25] Management and Governance - The company is currently managed by the daughters of the imprisoned founder, who has sold off shares worth 514 million over four years, raising concerns about governance and strategic direction [30][31] Cash Flow and Financial Health - Kew Flower Pharmaceutical has maintained strong cash flow, with a total operating cash inflow of 8.376 billion since 2014, indicating robust financial health [34] - The company has a low debt ratio, with a debt-to-asset ratio of 26.2% and a negligible interest-bearing debt ratio of 0.4% [34]

Group 1: Company Performance and Strategy - In the first half of 2024, the company achieved breakthroughs in R&D, ensuring a strong pipeline for future products despite a decline in operational indicators compared to the same period in 2023 [41] - The company has implemented strategic procurement and project management to stabilize raw material costs and enhance product quality and user experience [41] - The long-term development trend remains positive, supported by effective implementation of operational strategies [41] Group 2: Future Product Outlook - The company is focusing on a multi-faceted R&D approach, including "buy, modify, collaborate, research, and substitute" to acquire high-quality products [41] - New products such as liver protection tablets and pediatric cough syrup have received registration approval, with several other products in various stages of development [41] - The launch of these products is expected to significantly boost the company's revenue [41] Group 3: Dividend Policy - The company has maintained a high cash dividend ratio, with cumulative cash dividends of 2.651 billion since its listing, significantly exceeding the initial financing amount [41] - In 2023, the total cash dividend was 876 million, accounting for 78.27% of the net profit attributable to shareholders [41] - The company aims to continue providing high returns to investors while considering operational needs and future growth [41] Group 4: Market Trends and Preparedness - The company anticipates a peak in respiratory diseases during the autumn and winter seasons, with channels preparing inventory in advance to ensure smooth supply [41] - The seasonal characteristics of respiratory diseases indicate a high demand for related medications during this period [41]

第五届监事会第二次会议决议公告 证券代码：002737 证券简称：葵花药业 公告编号：2024-042 葵花药业集团股份有限公司 一、监事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届监事 会第二次会议于 2024 年 8 月 27 日以通讯方式召开。本次会议由公司监事会主席 何岩女士召集，会议通知及议案于 2024 年 8 月 16 日通过电子邮件形式发出。 会议应参加表决监事三人，实际参加表决监事三人，本次会议召集和召开程 序符合《公司法》及《公司章程》之规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 经审核，监事会认为，公司董事会编制和审议公司 2024 年半年度报告全文 及摘要的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏。 表决结果：同意 3 票，反对 0 票，弃权 0 票，通过。 2、审议通过《公司 2024 年半年度非经营性资金占用及其他关联资金往来 情况汇总表》 经审核，监事会认为，公司与其他关联方发 ...

葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第二次会议于 2024 年 8 月 27 日上午 9 时 30 分以通讯方式召开。会议由公司 董事长关玉秀女士召集，会议通知及议案于 2024 年 8 月 16 日通过电子邮件形式 发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司章程》 之规定，会议决议合法有效。 二、董事会会议审议情况 证券代码：002737 证券简称：葵花药业 公告编号：2024-041 葵花药业集团股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 专门委员会审议情况：本议案提交董事会审议前业经公司第五届董事会审计 委员会 2024 年第一次会议审议通过。 三、备查文件 1、公司第五届董事会第二次会议决议 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 同意公司 2024 年半年报及相关文件对外报出。其中，《2024 年半年度报告 全文》披露于本公司指定信息披露媒 ...

本表已于 2024 年 8 月 27 日获董事会批准。 公司负责人（法定代表人）：_________ 主管会计工作负责人：________ 会计机构负责人：________ 单位：万元 | | | 占用方与上市 | 上市公司核算的 | 2024年期初占 | 2024 年半年度 占用累计发生 | 2024 年半年 度占用资金 | 2024 年半年 | 2024 年半年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 公司的关联关 | | | | | 度偿还累计 | 度期末占用 | 占用形成原因 | 占用性质 | | | | 系 | 会计科目 | 用资金余额 | 金额（不含利 | 的利息(如 | 发生金额 | 资金余额 | | | | | | | | | 息） | 有) | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 15%[2]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2024, reflecting an expected growth of 10% compared to 2023[2]. - The company's operating revenue for the first half of 2024 was ¥2,527,602,096.82, a decrease of 16.69% compared to the same period last year[13]. - The net profit attributable to shareholders was ¥486,332,757.84, down 23.79% year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥459,706,530.01, reflecting a decline of 21.33% compared to the previous year[13]. - The total comprehensive income for the first half of 2024 was approximately CNY 585.46 million[136]. - The total profit for the first half of 2024 was CNY 640,201,259.56, down 21.5% from CNY 815,839,990.08 in the same period of 2023[118]. - The company reported a significant decrease in other payables from CNY 2,404,427,048.26 to CNY 1,435,950,576.62, a reduction of about 40.2%[115]. Market and Customer Growth - User data indicates a growth in active customers by 20%, reaching 5 million users by the end of June 2024[2]. - New product launches contributed to 30% of total sales in the first half of 2024, with significant demand for the latest pain relief medication[2]. - Market expansion efforts have led to a 25% increase in sales in the southern regions of China[2]. - The company continues to focus on the children's medication sector, enhancing the market position of the "XiaoKuaHua" brand, particularly in respiratory and cold medication[25]. Research and Development - The company is investing RMB 200 million in R&D for new technologies aimed at enhancing drug delivery systems[2]. - The company is pursuing a multi-channel R&D strategy, focusing on "buying" and "collaborating" to acquire high-quality products, with 7 classic formula research projects and 32 chemical drug projects underway[28]. - The company achieved breakthroughs in R&D, with several products receiving registration approvals and entering various stages of production, including 5 invention patents granted in health products[28]. - Research and development expenses increased by 8.91% to ¥51,434,495.15, up from ¥47,228,443.45 in the previous year[32]. Financial Management and Investments - The company plans to reinvest profits into business development rather than distributing cash dividends to shareholders[3]. - The company distributed cash dividends of 1.5 yuan per share, totaling 876 million yuan, which accounts for 78.27% of the annual net profit attributable to shareholders[30]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a focus on companies in the biopharmaceutical sector[2]. - The company reported a cash management progress announcement on June 5, 2024, regarding the use of idle self-owned funds[98]. Compliance and Risk Management - The management highlighted risks including raw material price fluctuations and increased market competition, which could impact future performance[3]. - The company is facing risks from industry policy changes, market competition, and fluctuations in raw material prices, and is implementing measures to enhance internal management and optimize business structure[48][50][51]. - The company emphasizes compliance and quality as core operational principles amidst industry changes, aiming for sustainable growth[24]. - The company is enhancing its compliance management and operational efficiency, ensuring effective governance and high inter-departmental collaboration[31]. Environmental Responsibility - The company has obtained pollution discharge permits for its subsidiaries, with validity periods ranging from 2023 to 2029[64]. - The company is committed to adhering to the latest environmental protection laws and standards, including the 2020 revisions of the Solid Waste Pollution Prevention Law[62]. - The company has implemented measures to manage and disclose environmental information as per the regulations[63]. - The company has achieved a reduction in waste emissions through the classification and recycling of packaging materials[73]. Shareholder and Corporate Governance - The annual shareholders' meeting had a participation rate of 53.16% on May 30, 2024, where several key proposals were approved, including the annual financial report and profit distribution plan[56]. - The first extraordinary shareholders' meeting of 2024 had a participation rate of 52.38% on June 25, 2024, resulting in the election of new board members and adjustments to management compensation[56]. - The company has maintained a good integrity status with no unfulfilled court judgments or significant debts due[85]. - The company has no significant guarantees during the reporting period[92]. Share Capital and Equity - The total number of shares outstanding as of June 30, 2024, is 584 million[138]. - The total number of ordinary shareholders at the end of the reporting period was 32,450, with the largest shareholder,葵花集团有限公司, holding 45.41% of shares, equating to 265,200,000 shares[101]. - The company has not engaged in any significant asset or equity sales during the reporting period[46]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[104]. Operational Efficiency - The company is implementing a transformation in the family medicine sector, promoting a renewal project and deepening organizational changes to enhance operational efficiency[26]. - The company has implemented automation upgrades in its packaging line and added air-cooled units, significantly reducing energy consumption per product[73]. - The company has optimized wastewater treatment processes, ensuring effective treatment for different wastewater characteristics[73]. - The company is focused on improving its environmental performance through the installation of advanced pollution control facilities[71].

证券代码：002737 证券简称：葵花药业 公告编号：2024-040 葵花药业集团股份有限公司 关于复方聚乙二醇（3350）电解质口服溶液 获得上市许可受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司（以下简称"哈葵花"）于近日收到国家药品监督管理 局下发的关于复方聚乙二醇（3350）电解质口服溶液申请注册上市许可的《受理 通知书》，现将有关情况公告如下： 一、药物的基本情况 上述药品在获国家药品监督管理局注册上市许可申请受理后，将转入国家药 品监督管理局药品审评中心进行审评审批，鉴于药品审评周期长、环节多，期间 可能受不确定性因素影响，具体完成时间、审批结果存在不确定性。提醒广大投 资者审慎决策，注意投资风险。 1 公司将积极推进该产品的上市许可工作并持续关注审批情况，及时履行信息 披露义务。 2、剂型：口服溶液剂 3、受理号：CYHS2402754 4、申请事项：境内生产药品注册上市许可 5、申请人：哈尔滨葵花药业有限公司 6、注册分类：化学药品 3 类 ...